Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Genomic Medicine and the Bioeconomy: Innovation for a Better World

May 12–16, 2014  •  Boston, MA

Genomic Medicine and the Bioeconomy: Innovation for a Better World

May 12–16, 2014  •  Boston, MA

Register Now

Program fee

$4,100

Program Overview

The Human Genome Project has revolutionized the field of life sciences and created new biological data and dramatic breakthroughs in gene sequencing technologies.

Applications for genomic medicine are now developing at a rapid speed. In addition to the medical community, potential applications involve many stakeholders, from government and regulatory agencies to the investor community to those focusing on science and technology as key drivers of economic development. Convergence of technologies — as in the case of synthetic biology — are resulting in the development of initial applications to meet global challenges, including health care, food and energy production, and the generation of new raw materials such as bioplastics, cosmetics, and lubricants, among many others. Current investment in the Human Genome Project shows that every dollar invested yields $140 in return, demonstrating the potential impact of genomics to the economy. Moreover, a recent report indicates that US federal investment in the genomic revolution has contributed to a total economic output of nearly $1 trillion.

This program will explore the implications of this rapid development in genomic medicine on the bioeconomy of countries around the world. It will review examples of applications, from genetic risk prediction to implications for public health pharmacogenomics and the economy, and how genetics will change the practice of medicine and global disease control.

Scientific and technological innovation in genomic medicine is having a significant impact in promoting emerging health care innovations for the clinical and public health practice and providing new engines for the knowledge economy. The Genomic Medicine and the Bioeconomy executive program at Harvard School of Public Health (HSPH) creates a unique forum for physicians and leaders in health care organizations, government, academia, industry, and civil society to focus on the direction and development of the bioeconomy. This program will provide an overview of genomic medicine for those with backgrounds in medicine and biology and highlight the role of genomics in medical innovation.

Key elements of the program include personalized medicine, genomics of infectious and non-infectious diseases, technologies for the diagnostics lab, and convergence of technologies.

HSPH is uniquely suited to offer Genomic Medicine and the Bioeconomy. HSPH and Harvard Medical School faculty have played key roles in advancing the field. Examples include genome sequencing to trace the path of mass pathogens, conducting genome-wide association studies of cancers, and advancing the field of quantitative genomics through an interdisciplinary focus on genetics, behavior, environment, and medicine.

SOURCE

https://ecpe.sph.harvard.edu/programs.cfm?CSID=GMB0000&pg=cluster&CLID=1